Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reissue Patent
2007-04-03
2007-04-03
Huff, Sheela J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388230, C424S133100, C424S145100, C435S335000, C435S328000, C435S069600, C435S069700
Reissue Patent
active
10012579
ABSTRACT:
An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
REFERENCES:
patent: 5585089 (1996-12-01), Queen et al.
patent: 5998586 (1999-12-01), Bodmer et al.
patent: 0120694 (1984-03-01), None
patent: 0 239 400 (1984-08-01), None
patent: 0125023 (1984-11-01), None
patent: 0 125 023 (1984-11-01), None
patent: A 0239400 (1987-09-01), None
patent: 0 120 694 (2002-02-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 93/16184 (1993-08-01), None
patent: WO 93/16814 (1993-09-01), None
Rudikoff et al Proc NAtl Acad Sci USA vol. 79:1979.
Maniatis et al., “Molecular Cloning: A Laboratory Manual,” vols. 1-3, Second Edition, Cold Spring Harbor Laboratory Press (1989).
Bergent, et al.,Br. J. Cancer, 62. 487, (1990).
Cockett, et al.,Nucl. Acids Res.,19, 319-325 (1991).
Jones, P. et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse”.Nature,321, 522-525, (1986).
Queen, et al., “A humanized antibody that binds to the interleukin 2 receptor”,Proc. Natl. Acad. Sci. USA,86, 10029-10033 (1989).
Riechmann, et al., “Reshaping human antibodies for therapy”,Nature,332, 323-327 (1988).
Verhoeyen, et al.,Science,239, 1534-1536 (19888).
Rudikoff et al Proc Natl Acad Sci USA vol. 79:1979, 1982.
Bergent, R.H.J. et al., “Phase I/II Study of Chimeric B72.3 Antibody in Radioimmunotherapy of Colorectal Carcinoma,”British Journal Cancer., 62:487, (1990), Cancer Research Campaign Laboratories, Charing Cross Hospital, London and Celltech Ltd., Slough, United Kingdom.
Cockett, Mark I. et al., “The Use of Engineered E1A Genes to Transactivate the hCMV-MIE Promoter in Permanent CHO Cell Lines.”Nucleic Acids Res., 19(2):319-325, (1991), Celltech Ltd., Slough, United Kingdom.
Jones, Peter T. et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,”Nature, 321:522-525, (1986), Laboratory of Molecular Biology, Medical Research Council, Cambridge, United Kingdom.
Kabat et al., “Sequences of Proteins of Immunological Interest,”1987, U.S. Dept. of Health and Human Services, National Institute of Health, USA.
Kabat et al., “Sequences of Proteins of Immunological Interest,” vol. I, Fifth Edition, 1991, U.S. Dept. of Health and Human Services, National Institute of Health, USA.
Mauser, Peter J. et al., “Effects of an Antibody to Interleukin-5 in a Monkey Model of Asthma,”Am. J. Respir. Crit. Care Med., 152:467-472, (1995), Department of Allergy, Schering-Plough Research Institute, Kenilworth, New Jersey.
Queen, Cary L. et al., “A humanized antibody that binds to the interleukin 2 receptor,”Proc. Natl. Acad. Sci. USA, 86:10029-10033, (1989), Protein Design Labs, Palo Alto, CA, Department of Cell Biology, Stanford University, Stanford, CA and Metabolisan Branch, National Cancer Institute, National Institute of Health, Bethesda, MD.
Riechmann, Lutz et al., “Reshaping human antibodies for therapy,”Nature, 332:323-327, (1988), MRC Laboratory of Molecular Biology, Cambridge, United Kingdom, Department of Pathology, University of Cambrigde, Cambridge, United Kingdom.
Rudikoff Stuart et al., “Single amino acid substitution altering antigen-binding specificity,”Proc. Natl. Acad. Sci USA, 79:1979-1983 (1982), Laboratory of Cell Biology, National institutes of Health, Bethesda, MD and Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY.
Verhoeyen, Martine et al., “Reshaping Human Antibodies: Grafting on Antilysozyme Activity,”Science, 239:1534-1536, (1988), Medical Research Council Laboratory of Moleular Biology, Cambridge, England.
Athwal Diljeet Singh
Bodmer Mark William
Emtage John Spencer
Celltech R&D Limited
Huff Sheela J.
O'Connor P.C. Cozen
Trujillo Doreen Y.
LandOfFree
Interleukin-5 specific recombinant antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interleukin-5 specific recombinant antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interleukin-5 specific recombinant antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3755038